CS
INFI

Credit Suisse’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Credit Suisse’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-27,252
Closed -$37K – 4136
2016
Q4 		$37K Sell
27,252
-222,345
-89% -$290K ﹤0.01% 4046
2016
Q3 		$389K Sell
249,597
-64,584
-21% -$99.2K ﹤0.01% 3542
2016
Q2 		$418K Buy
314,181
+20,734
+7% +$97K ﹤0.01% 3526
2016
Q1 		$1.55M Buy
293,447
+72,466
+33% +$443K ﹤0.01% 2397
2015
Q4 		$1.74M Sell
220,981
-28,811
-12% -$248K ﹤0.01% 2386
2015
Q3 		$2.11M Sell
249,792
-37,811
-13% -$349K ﹤0.01% 2221
2015
Q2 		$3.15M Buy
287,603
+61,764
+27% +$793K ﹤0.01% 2169
2015
Q1 		$3.16M Buy
225,839
+46,309
+26% +$708K ﹤0.01% 2029
2014
Q4 		$3.03M Buy
179,530
+22,092
+14% +$322K ﹤0.01% 2182
2014
Q3 		$2.11M Sell
157,438
-204,520
-57% -$2.44M ﹤0.01% 2442
2014
Q2 		$4.61M Sell
361,958
-100,199
-22% -$1.04M ﹤0.01% 2035
2014
Q1 		$5.49M Buy
462,157
+117,906
+34% +$1.58M 0.01% 1686
2013
Q4 		$4.75M Buy
344,251
+128,925
+60% +$1.82M ﹤0.01% 1891
2013
Q3 		$3.75M Buy
215,326
+29,155
+16% +$558K ﹤0.01% 1876
2013
Q2 		$3.02M Buy
+186,171
New +$5.76M ﹤0.01% 1967

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Credit Suisse's INFI Position: Q1 2017 in Review

Credit Suisse sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2017, closing a stake of 27,252 shares — an estimated $37K sold.

Credit Suisse first reported a position in INFI in Q2 2013 and held it in 15 quarters. The position peaked at $5.49M in Q1 2014. 80 funds tracked by Wall St. Rank hold INFI as of Q1 2017.

  • Credit Suisse reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Credit Suisse sold 27,252 Infinity Pharmaceuticals, Inc. shares in Q1 2017, an estimated $37K.
  • Credit Suisse first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 15 quarters.
  • Credit Suisse's Infinity Pharmaceuticals, Inc. position peaked at $5.49M in Q1 2014.
  • 80 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2017.

Based on Credit Suisse's 13F filing for Q1 2017, filed 15 May 2017.